Overview of drugs approved by the FDA in 2022

Author:

Kurkin D. V.1ORCID,Morkovin E. I.2ORCID,Bakulin D. A.2ORCID,Gorbunova Yu. V.2ORCID,Kolosov Yu. A.3ORCID,Dzhavakhyan M. A.4ORCID,Makarenko I. E.5ORCID,Drai R. V.6ORCID,Zaborovsky A. V.3ORCID,Shatalova O. V.2ORCID,Strygin A. V.2ORCID,Petrov V. I.2ORCID,Pleten A. P.3ORCID,Prokopov A. A.3ORCID,Tatarenko-Kozmina T. Yu.3ORCID

Affiliation:

1. 1.Yevdokimov Moscow State University of Medicine and Dentistry. 2.Volgograd State Medical University.

2. Volgograd State Medical University

3. Yevdokimov Moscow State University of Medicine and Dentistry

4. 1.Yevdokimov Moscow State University of Medicine and Dentistry. 2.All-Russian Scientific Research Institute of Medicinal and Aromatic Plants.

5. 1.Yevdokimov Moscow State University of Medicine and Dentistry. 2.Farm-Holding

6. Farm-Holding

Abstract

The aim of the work is to conduct a review of medications approved by the FDA in 2022.Materials and methods. In searching for the materials to write this review article, bibliographic databases including PubMed, Google Scholar and e-library.ru were utilized. The search was conducted for the publications spanning the period from 2008 to 2023. Herewith, the following keywords and word combinations were used: new drug approval, NDA, drug authorization, approval package, breakthrough medicine.Results. The discovery and development of medications are among the most crucial scientific processes in healthcare. Developing a new drug is a highly intricate, expensive, and time-consuming process. Nowadays, the problem of costs reduction and the process of expedited discovering of new medications are particularly pertinent. To optimize the search for active compounds, virtual and high-throughput screenings, machine learning, artificial intelligence, cryo-electron microscopy, and drug repurposing are employed. Simultaneously, the search for original molecules to serve as the basis for innovative drugs continues. This article presents a review of medications approved by the FDA in 2022 for the treatment of various pathologies.Conclusion. A drug development is a complex and resource-intensive process, with only a small fraction of candidates advancing to clinical trials. A drug design evolves in tandem with societal needs, and this review highlights some of the medications approved by the FDA in 2022. Technological advancements are expected to expedite drug development, potentially reducing the time to the market. Biotechnology, including cell therapy, holds significant prospects, and achievements in genetic mapping and chip technologies will enhance the accessibility of personalized pharmacology.

Publisher

Volgograd State Medical University

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology,Pharmacy,Pharmacology (nursing)

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3